Products - Children and teenagers | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 96 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
28 July 2021
Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 June 2025
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 March 2025
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 February 2025
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (TA1034)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 January 2025
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 January 2025
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 January 2024
Risdiplam for treating spinal muscular atrophy (TA755)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
15 December 2023
Published:
16 December 2021
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 July 2022
Palforzia for treating peanut allergy in children and young people (TA769)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2021
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 October 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 July 2021
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 December 2019
Cochlear implants for children and adults with severe to profound deafness (TA566)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2019
Dinutuximab beta for treating neuroblastoma (TA538)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2018
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 July 2017
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2013
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 January 2011
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2010
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 July 2025
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for children with severe atopic dermatitis [TSID10434]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [TSID10237]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant [TS ID 11868]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older [ID6542]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [TSID11996]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [TSID12142]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Clascoterone for treating acne vulgaris in people 12 years and over [TSID12136]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [TSID12131]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lebrikizumab for treating atopic dermatitis in children [TSID12133]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC